| 名稱 | ADCC Bioassay Effector Cell F variant （Low Affinit |
| 型號 | CBP74002 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | ADCC Bioassay Effector Cell F variant （Low Affinity）- Fcγ-NFAT/Jurkat,母細(xì)胞：Jurkat，培養(yǎng)基：1640+10%FBS |
產(chǎn)品搜索
相關(guān)文章
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74002ADCC Bioassay Effector Cell F variant （Low Affinit
- 詳細(xì)內(nèi)容
| I. Background | |
抗體依賴的細(xì)胞介導(dǎo)的細(xì)胞毒性作用（ADCC，antibody-dependent cell-mediated cytotoxicity ）是指抗體的 Fab 段結(jié)合病毒感染的細(xì)胞或腫瘤細(xì)胞的抗原表位，其 Fc 段與殺 傷細(xì)胞（NK 細(xì)胞、巨噬細(xì)胞等）表面的 FcR 結(jié)合，介導(dǎo)殺傷細(xì)胞直接殺傷靶細(xì)胞，它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機(jī)制。 | |
| II. Description | |
ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat 報(bào)告基因藥靶模型 很好的模擬了體內(nèi) ADCC 的信號轉(zhuǎn)導(dǎo)過程，原理見下圖所示。
| |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-CD16(F158) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS |
| Mycoplasma Testing: | Negative |
| Storage: | Immediately upon receipt, store in liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Recombinant ADCC Bioassay Effector Cell F variant (Low Affinity)- Fcγ-NFAT/Jurkat expressing CD16.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell F variant (Low Affinity)-Fcγ-NFAT Jurkat (C11) with Raji.
" _ue_custom_node_="true">
